Terms: = Bone cancer AND IRF4, LSIRF, 3662, ENSG00000137265, Q15306 AND Prognosis
10 results:
1. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with irf4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract] [Full Text] [Related]
2. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
3. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract] [Full Text] [Related]
4. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
Melaiu O; Macauda A; Sainz J; Calvetti D; Facioni MS; Maccari G; Ter Horst R; Netea MG; Li Y; Grząśko N; Moreno V; Jurczyszyn A; Jerez A; Watek M; Varkonyi J; Garcia-Sanz R; Kruszewski M; Dudziński M; Kadar K; Jacobsen SEH; Mazur G; Andersen V; Rybicka M; Zawirska D; Raźny M; Zaucha JM; Ostrovsky O; Iskierka-Jazdzewska E; Reis RM; Stępień A; Beider K; Nagler A; Druzd-Sitek A; Marques H; Martìnez-Lopez J; Lesueur F; Avet-Loiseau H; Vangsted AJ; Krawczyk-Kulis M; Butrym A; Jamroziak K; Dumontet C; Vogel U; Rymko M; Pelosini M; Subocz E; Szombath G; Sarasquete ME; Silvestri R; Morani F; Landi S; Campa D; Canzian F; Gemignani F
Int J Cancer; 2021 Apr; 148(8):1887-1894. PubMed ID: 33152124
[TBL] [Abstract] [Full Text] [Related]
5. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract] [Full Text] [Related]
6. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
[TBL] [Abstract] [Full Text] [Related]
7. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract] [Full Text] [Related]
8. Total en bloc spondylectomy for lung cancer metastasis to the spine.
Murakami H; Kawahara N; Demura S; Kato S; Yoshioka K; Tomita K
J Neurosurg Spine; 2010 Oct; 13(4):414-7. PubMed ID: 20887137
[TBL] [Abstract] [Full Text] [Related]
9. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
McMillin DW; Delmore J; Weisberg E; Negri JM; Geer DC; Klippel S; Mitsiades N; Schlossman RL; Munshi NC; Kung AL; Griffin JD; Richardson PG; Anderson KC; Mitsiades CS
Nat Med; 2010 Apr; 16(4):483-9. PubMed ID: 20228816
[TBL] [Abstract] [Full Text] [Related]
10. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract] [Full Text] [Related]
